At the European Cancer Congress (ECC) 2015, Clifford A. Hudis, MD, of Memorial Sloan Kettering Cancer Center, New York, NY, discusses the low-risk registry results from Trial Assigning IndividuaLized Options for Treatment (TAILORx), which is a prospective phase 3 clinical trial designed to evaluate the role of endocrine therapy and chemoendocrine therapy in patients with oestrogen receptor (ER)-positive, HER2-negative, axillary node-negative breast cancer whose treatment was guided by the 21-gene expression assay results, the Oncotype DX® Breast Cancer Assay Recurrence Score® results.
